Literature DB >> 19402205

Lack of evidence for bacterial infections in skin in patients with systemic sclerosis.

Maureen D Mayes1, Judith A Whittum-Hudson, Cynthia Oszust, Hervé C Gérard, Alan P Hudson.   

Abstract

BACKGROUND: In some patients with systemic sclerosis (SSc), persistent bacterial infection involving dermal microvascular endothelial cells may result in endothelial injury, leading to the obliterative microvasculopathy typical of the disease. Alternatively, in some patients with SSc persistent bacterial infection involving activated dermal fibroblasts or other cells found in scleroderma skin might result in the fibrosing features of this disease. In this study, we investigated bacterial infection in skin in patients with SSc.
METHODS: Chlamydiae of many species are known to undergo persistent infection. Highly sensitive and specific PCR assays targeting chromosomal DNA sequences from C. trachomatis and C. pneumoniae were used to screen skin biopsy samples from each of 18 patients and 26 control individuals. Additional screening was performed using a highly sensitive "pan-bacteria" PCR screening system.
RESULTS: All patient and control samples proved to be PCR-negative for both chlamydial species. Similarly, all patient and control samples were PCR-negative when the broad range pan-bacteria assay system was used.
CONCLUSION: Although some caveats apply, the data presented here do not support the contention that persistent bacterial infections play an important role in the pathogenesis of SSc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19402205      PMCID: PMC2748399          DOI: 10.1097/maj.0b013e3181891612

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  16 in total

1.  Systemic sclerosis following human cytomegalovirus infection.

Authors:  C Ferri; M Cazzato; D Giuggioli; M Sebastiani; C Magro
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

2.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

Review 3.  Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis.

Authors:  J P Pandey; E C LeRoy
Journal:  Arthritis Rheum       Date:  1998-01

4.  Macrovascular disease and systemic sclerosis.

Authors:  M Ho; D Veale; C Eastmond; G Nuki; J Belch
Journal:  Ann Rheum Dis       Date:  2000-01       Impact factor: 19.103

5.  Chlamydia pneumoniae present in the human synovium are viable and metabolically active.

Authors:  H C Gérard; H R Schumacher; H El-Gabalawy; R Goldbach-Mansky; A P Hudson
Journal:  Microb Pathog       Date:  2000-07       Impact factor: 3.738

6.  Chromosomal DNA from a variety of bacterial species is present in synovial tissue from patients with various forms of arthritis.

Authors:  H C Gérard; Z Wang; G F Wang; H El-Gabalawy; R Goldbach-Mansky; Y Li; W Majeed; H Zhang; N Ngai; A P Hudson; H R Schumacher
Journal:  Arthritis Rheum       Date:  2001-07

7.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

Review 8.  Vascular complications of scleroderma.

Authors:  Serena Guiducci; Roberto Giacomelli; Marco Matucci Cerinic
Journal:  Autoimmun Rev       Date:  2007-01-12       Impact factor: 9.754

9.  Increased prevalence of human parvovirus B19 DNA in systemic sclerosis skin.

Authors:  T Ohtsuka; S Yamazaki
Journal:  Br J Dermatol       Date:  2004-06       Impact factor: 9.302

10.  Differential expression of three Chlamydia trachomatis hsp60-encoding genes in active vs. persistent infections.

Authors:  Hervé C Gérard; Judith A Whittum-Hudson; H Ralph Schumacher; Alan P Hudson
Journal:  Microb Pathog       Date:  2004-01       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.